Address correspondence to Dr Robert H. Gross, Anschutz Outpatient Pavilion, Mail Stop F727, 1635 Aurora Ct, 5th Floor, Aurora, CO 80045, Robert.Gross@ucdenver.edu.
RELATIONSHIP DISCLOSURE: Dr Gross reports no disclosure. Dr Corboy serves as editor of Neurology Clinical Practice, as a consultant for a legal matter for Mylan NV, and on the research steering committee for Novartis AG. Dr Corboy has received personal compensation for speaking engagements from PRIME Education, LLC, and the Rocky Mountain Multiple Sclerosis Center and receives research/grant support from MedDay Pharmaceuticals, the National Multiple Sclerosis Society, Novartis AG, and the Patient-Centered Outcomes Research Institute. Dr Corboy has served as a consultant on medicolegal proceedings for medical malpractice.
UNLABELED USE OF PRODUCTS/INVESTIGATIONAL USE DISCLOSURE: Drs Gross and Corboy discuss the unlabeled/investigational use of cyclophosphamide and rituximab for the treatment of multiple sclerosis.